BACKGROUND: Choroid plexus tumors (CPT) are rare pediatric tumors. A population-based study on choroid plexus carcinoma (CPC) and choroid plexus papilloma (CPP) was carried out to describe the incidence, demographic, and outcome data and to identify potential prognostic factors. METHODS: The CPT population from the Canadian databank of CNS tumor in children ≤ 36 months diagnosed between 1990 and 2005 was reviewed RESULTS: Out of the 579 reported cases of CNS tumors, 37 were CPT. The annual age-adjusted incidence rate was 0.22 + 0.12 (95% CI 0.16-0.28)/100,000 children < 3 years. There were 21 (56.7%) CPP and 16 (43.3.5%) CPC. Twenty patients (54%) were males. Median age at diagnosis was 7 months(range 0-30). Ten patients(62.5%) with CPC and one with CPP were metastatic at diagnosis. Twenty patients with CPP (95%) had a complete resection, whereas 6/16 CPC (37.5%) achieved a resection >90%. Fourteen CPC patients received adjuvant chemotherapy. None of the 37 patients received adjuvant radiation. At completion of survey, all CPP and five CPC were alive. Median survival time for CPC patients was 15 months (0-120). One death was related to intraoperative hemorrhage, another to chemotherapy-induced toxicity, and one to secondary AML. Age at diagnosis, degree of resection and metastatic status were not significant prognostic factors for CPC. CONCLUSION: By contrast to CPC, CPP have an excellent prognosis following surgery alone. Survival of CPC remains poor. However, these data may suggest adjuvant chemotherapy can alter the aggressive natural history of CPC. As with other rare CNS tumors, international collaboration is required to identify optimal therapy.
BACKGROUND:Choroid plexus tumors (CPT) are rare pediatric tumors. A population-based study on choroid plexus carcinoma (CPC) and choroid plexus papilloma (CPP) was carried out to describe the incidence, demographic, and outcome data and to identify potential prognostic factors. METHODS: The CPT population from the Canadian databank of CNS tumor in children ≤ 36 months diagnosed between 1990 and 2005 was reviewed RESULTS: Out of the 579 reported cases of CNS tumors, 37 were CPT. The annual age-adjusted incidence rate was 0.22 + 0.12 (95% CI 0.16-0.28)/100,000 children < 3 years. There were 21 (56.7%) CPP and 16 (43.3.5%) CPC. Twenty patients (54%) were males. Median age at diagnosis was 7 months(range 0-30). Ten patients(62.5%) with CPC and one with CPP were metastatic at diagnosis. Twenty patients with CPP (95%) had a complete resection, whereas 6/16 CPC (37.5%) achieved a resection >90%. Fourteen CPC patients received adjuvant chemotherapy. None of the 37 patients received adjuvant radiation. At completion of survey, all CPP and five CPC were alive. Median survival time for CPC patients was 15 months (0-120). One death was related to intraoperative hemorrhage, another to chemotherapy-induced toxicity, and one to secondary AML. Age at diagnosis, degree of resection and metastatic status were not significant prognostic factors for CPC. CONCLUSION: By contrast to CPC, CPP have an excellent prognosis following surgery alone. Survival of CPC remains poor. However, these data may suggest adjuvant chemotherapy can alter the aggressive natural history of CPC. As with other rare CNS tumors, international collaboration is required to identify optimal therapy.
Authors: R J Packer; G Perilongo; D Johnson; L N Sutton; G Vezina; R A Zimmerman; J Ryan; G Reaman; L Schut Journal: Cancer Date: 1992-01-15 Impact factor: 6.860
Authors: E Chow; D A Reardon; A B Shah; J J Jenkins; J Langston; R L Heideman; R A Sanford; L E Kun; T E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 1999-05-01 Impact factor: 7.038
Authors: P K Duffner; L E Kun; P C Burger; M E Horowitz; M E Cohen; R A Sanford; J P Krischer; R K Mulhern; H E James; H L Rekate Journal: Pediatr Neurosurg Date: 1995 Impact factor: 1.162
Authors: Brigitte Wrede; Martin Hasselblatt; Ove Peters; Peter F Thall; Tezer Kutluk; Albert Moghrabi; Anita Mahajan; Stefan Rutkowski; Blanca Diez; Xuemei Wang; Torsten Pietsch; Rolf-Dieter Kortmann; Werner Paulus; Astrid Jeibmann; Johannes E A Wolff Journal: J Neurooncol Date: 2009-06-20 Impact factor: 4.130
Authors: Birgit V Nimmervoll; Nidal Boulos; Brandon Bianski; Jason Dapper; Michael DeCuypere; Anang Shelat; Sabrina Terranova; Hope E Terhune; Amar Gajjar; Yogesh T Patel; Burgess B Freeman; Arzu Onar-Thomas; Clinton F Stewart; Martine F Roussel; R Kipling Guy; Thomas E Merchant; Christopher Calabrese; Karen D Wright; Richard J Gilbertson Journal: Clin Cancer Res Date: 2018-01-04 Impact factor: 12.531
Authors: Roy W R Dudley; Michelle R Torok; Danielle Gallegos; Arthur K Liu; Michael H Handler; Todd C Hankinson Journal: J Neurooncol Date: 2014-10-09 Impact factor: 4.130
Authors: Matthew Z Sun; Michael E Ivan; Aaron J Clark; Michael C Oh; Arthur R Delance; Taemin Oh; Michael Safaee; Gurvinder Kaur; Orin Bloch; Annette Molinaro; Nalin Gupta; Andrew T Parsa Journal: J Neurooncol Date: 2013-10-29 Impact factor: 4.130
Authors: A Siegfried; S Morin; C Munzer; M B Delisle; M Gambart; S Puget; C A Maurage; C Miquel; C Dufour; P Leblond; N André; D Figarella Branger; J Kanold; J-L Kemeny; C Icher; A Vital; E Uro Coste; A I Bertozzi Journal: J Neurooncol Date: 2017-07-04 Impact factor: 4.130